dales pharmaceuticals limited
dales pharmaceuticals limited Company Information
Company Number
00474958
Next Accounts
Mar 2026
Shareholders
veneto limited
Group Structure
View All
Industry
Non-trading company
Registered Address
24, cheshire avenue, cheshire busine, northwich, cheshire, CW9 7UA
Website
http://dechra.comdales pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DALES PHARMACEUTICALS LIMITED at £0 based on a Turnover of £0 and 0.58x industry multiple (adjusted for size and gross margin).
dales pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DALES PHARMACEUTICALS LIMITED at £0 based on an EBITDA of £0 and a 4.1x industry multiple (adjusted for size and gross margin).
dales pharmaceuticals limited Estimated Valuation
Pomanda estimates the enterprise value of DALES PHARMACEUTICALS LIMITED at £2 based on Net Assets of £2 and 1.35x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Dales Pharmaceuticals Limited Overview
Dales Pharmaceuticals Limited is a live company located in northwich, CW9 7UA with a Companies House number of 00474958. It operates in the non-trading company sector, SIC Code 74990. Founded in November 1949, it's largest shareholder is veneto limited with a 100% stake. Dales Pharmaceuticals Limited is a mature, unknown sized company, Pomanda has estimated its turnover at £0 with unknown growth in recent years.
Upgrade for unlimited company reports & a free credit check
Dales Pharmaceuticals Limited Health Check
There is insufficient data available to calculate a health check for Dales Pharmaceuticals Limited. Company Health Check FAQs
0 Strong
0 Regular
1 Weak
Size
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Growth
There is insufficient data available for this Key Performance Indicator!
- Dales Pharmaceuticals Limited
- - Industry AVG
Production
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Profitability
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Employees
with 1 employees, this is below the industry average (38)
- Dales Pharmaceuticals Limited
- - Industry AVG
Pay Structure
There is insufficient data available for this Key Performance Indicator!
- Dales Pharmaceuticals Limited
- - Industry AVG
Efficiency
There is insufficient data available for this Key Performance Indicator!
- Dales Pharmaceuticals Limited
- - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Creditor Days
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Stock Days
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Cash Balance
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
Debt Level
There is insufficient data available for this Key Performance Indicator!
- - Dales Pharmaceuticals Limited
- - Industry AVG
DALES PHARMACEUTICALS LIMITED financials
Dales Pharmaceuticals Limited's latest turnover from June 2024 is 0 and the company has net assets of £2. According to their latest financial statements, we estimate that Dales Pharmaceuticals Limited has 1 employee and maintains cash reserves of 0 as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | |||||||||||||||
| Other Income Or Grants | |||||||||||||||
| Cost Of Sales | |||||||||||||||
| Gross Profit | |||||||||||||||
| Admin Expenses | |||||||||||||||
| Operating Profit | |||||||||||||||
| Interest Payable | |||||||||||||||
| Interest Receivable | |||||||||||||||
| Pre-Tax Profit | |||||||||||||||
| Tax | |||||||||||||||
| Profit After Tax | |||||||||||||||
| Dividends Paid | 314,998 | ||||||||||||||
| Retained Profit | -314,998 | ||||||||||||||
| Employee Costs | |||||||||||||||
| Number Of Employees | |||||||||||||||
| EBITDA* |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | |||||||||||||||
| Intangible Assets | |||||||||||||||
| Investments & Other | |||||||||||||||
| Debtors (Due After 1 year) | |||||||||||||||
| Total Fixed Assets | |||||||||||||||
| Stock & work in progress | |||||||||||||||
| Trade Debtors | |||||||||||||||
| Group Debtors | 2 | 2 | 2 | 2 | 315,000 | 315,000 | |||||||||
| Misc Debtors | |||||||||||||||
| Cash | |||||||||||||||
| misc current assets | |||||||||||||||
| total current assets | 2 | 2 | 2 | 2 | 315,000 | 315,000 | |||||||||
| total assets | 2 | 2 | 2 | 2 | 315,000 | 315,000 | |||||||||
| Bank overdraft | |||||||||||||||
| Bank loan | |||||||||||||||
| Trade Creditors | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| other short term finances | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| other current liabilities | |||||||||||||||
| total current liabilities | |||||||||||||||
| loans | |||||||||||||||
| hp & lease commitments | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| other liabilities | |||||||||||||||
| provisions | |||||||||||||||
| total long term liabilities | |||||||||||||||
| total liabilities | |||||||||||||||
| net assets | 2 | 2 | 2 | 2 | 315,000 | 315,000 | |||||||||
| total shareholders funds | 2 | 2 | 2 | 2 | 315,000 | 315,000 |
| Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 | Jun 2020 | Jun 2019 | Jun 2018 | Jun 2017 | Jun 2016 | Jun 2015 | Jun 2014 | Jun 2013 | Jun 2012 | Jun 2011 | Jun 2010 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||||||||
| Operating Profit | |||||||||||||||
| Depreciation | |||||||||||||||
| Amortisation | |||||||||||||||
| Tax | |||||||||||||||
| Stock | |||||||||||||||
| Debtors | -314,998 | 315,000 | |||||||||||||
| Creditors | |||||||||||||||
| Accruals and Deferred Income | |||||||||||||||
| Deferred Taxes & Provisions | |||||||||||||||
| Cash flow from operations | 314,998 | -315,000 | |||||||||||||
| Investing Activities | |||||||||||||||
| capital expenditure | |||||||||||||||
| Change in Investments | |||||||||||||||
| cash flow from investments | |||||||||||||||
| Financing Activities | |||||||||||||||
| Bank loans | |||||||||||||||
| Group/Directors Accounts | |||||||||||||||
| Other Short Term Loans | |||||||||||||||
| Long term loans | |||||||||||||||
| Hire Purchase and Lease Commitments | |||||||||||||||
| other long term liabilities | |||||||||||||||
| share issue | |||||||||||||||
| interest | |||||||||||||||
| cash flow from financing | 315,000 | ||||||||||||||
| cash and cash equivalents | |||||||||||||||
| cash | |||||||||||||||
| overdraft | |||||||||||||||
| change in cash |
dales pharmaceuticals limited Credit Report and Business Information
Dales Pharmaceuticals Limited Competitor Analysis
Perform a competitor analysis for dales pharmaceuticals limited by selecting its closest rivals, whether from the PROFESSIONAL, SCIENTIFIC AND TECHNICAL ACTIVITIES sector, other mature companies, companies in CW9 area or any other competitors across 12 key performance metrics.
dales pharmaceuticals limited Ownership
DALES PHARMACEUTICALS LIMITED group structure
Dales Pharmaceuticals Limited has no subsidiary companies.
Ultimate parent company
FREYA POOLCO SARL
#0168355
2 parents
DALES PHARMACEUTICALS LIMITED
00474958
dales pharmaceuticals limited directors
Dales Pharmaceuticals Limited currently has 3 directors. The longest serving directors include Mr Paul Sandland (Nov 2023) and Miss Melanie Hall (Apr 2024).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Paul Sandland | England | 46 years | Nov 2023 | - | Director |
| Miss Melanie Hall | United Kingdom | 55 years | Apr 2024 | - | Director |
| Mr Jesper Nordengaard | United Kingdom | 49 years | Jun 2024 | - | Director |
P&L
June 2024turnover
0
0%
operating profit
0
0%
gross margin
0%
0%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
June 2024net assets
2
0%
total assets
2
0%
cash
0
0%
net assets
Total assets minus all liabilities
dales pharmaceuticals limited company details
company number
00474958
Type
Private limited with Share Capital
industry
74990 - Non-trading company
incorporation date
November 1949
age
76
incorporated
UK
ultimate parent company
accounts
Dormant
last accounts submitted
June 2024
previous names
N/A
accountant
-
auditor
-
address
24, cheshire avenue, cheshire busine, northwich, cheshire, CW9 7UA
Bank
-
Legal Advisor
-
dales pharmaceuticals limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We found 8 charges/mortgages relating to dales pharmaceuticals limited. Currently there are 0 open charges and 8 have been satisfied in the past.
dales pharmaceuticals limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for DALES PHARMACEUTICALS LIMITED. This can take several minutes, an email will notify you when this has completed.
dales pharmaceuticals limited Companies House Filings - See Documents
| date | description | view/download |
|---|
